A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led study Meeting Abstract


Authors: Cohen, D. J.; Christos, P. J.; Sparano, J. A.; Kindler, H. L.; Catenacci, D. V. T.; Bekaii-Saab, T. B.; Tahiri, S.; Janjigian, Y. Y.; Gibson, M. K.; Chan, E.; Rajdev, L.; Urba, S.; Wade, J. L.; Kozuch, P.; Love, E.; Vandris, K.; Takebe, N.; Hochster, H. S.
Abstract Title: A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led study
Meeting Title: 2013 Gastrointestinal Cancers Symposium
Journal Title: Journal of Clinical Oncology
Volume: 31
Issue: 4 Suppl.
Meeting Dates: 2013 Jan 24-26
Meeting Location: San Francisco, CA
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2013-02-01
Language: English
ACCESSION: WOS:000333679000069
DOI: 10.1200/jco.2013.31.4_suppl.67
PROVIDER: wos
Notes: Meeting Abstract: 67 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Yelena Yuriy Janjigian
    394 Janjigian